Inclisiran (Leqvio) During Pregnancy and Lactation: What the Evidence Actually Shows

How Inclisiran Works: The siRNA Mechanism Behind Leqvio

Inclisiran is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs the molecule specifically to hepatocyte asialoglycoprotein receptors. Once internalized, the siRNA engages the RNA-induced silencing complex (RISC) and catalytically degrades messenger RNA encoding proprotein convertase subtilisin/kexin type 9 (PCSK9). The result: the liver produces less PCSK9 protein, LDL receptors on hepatocyte surfaces are recycled rather than degraded, and circulating LDL-cholesterol drops.

This mechanism differs fundamentally from monoclonal antibody PCSK9 inhibitors like evolocumab and alirocumab, which neutralize PCSK9 protein after it has already been secreted into plasma. Inclisiran silences production at the mRNA level inside the hepatocyte. A single 284 mg subcutaneous injection suppresses circulating PCSK9 concentrations by approximately 75% to 80%, with LDL-C reductions near 50% sustained over 18 months in the ORION-10 and ORION-11 trials (N=3,178 combined).

The pharmacokinetic profile matters for reproductive safety discussions. Inclisiran's plasma half-life is short (roughly 9 hours), but the RISC-loaded siRNA persists inside hepatocytes for months. That prolonged pharmacodynamic effect means that even after the drug is undetectable in blood, PCSK9 suppression continues for approximately 6 months. This creates a practical challenge for pregnancy planning that does not exist with daily oral statins, which clear within hours of the last dose.

What the FDA Label Says About Pregnancy

The Leqvio prescribing information, approved by the FDA in December 2021, states plainly that there are no available data on inclisiran use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or adverse maternal outcomes. No human pregnancy exposure data exist because all key ORION program trials excluded women who were pregnant, planning pregnancy, or breastfeeding.

The label does include animal reproduction data. In embryo-fetal development studies conducted in rats and rabbits, subcutaneous inclisiran administered during organogenesis at doses producing maternal exposures up to approximately 30 times the human exposure at the recommended 284 mg dose did not produce teratogenicity or embryo-fetal toxicity. In a pre- and postnatal development study in rats, no adverse developmental effects were observed at similar multiples of human exposure.

These findings are reassuring at a preclinical level, but they carry well-known translational limitations. As Dr. Anne Goldberg, an endocrinologist at Washington University School of Medicine, has noted: "Negative animal reproductive data reduce concern but cannot substitute for controlled human exposure data, particularly for a first-in-class therapeutic modality like hepatocyte-targeted siRNA."

The label does not assign a legacy FDA pregnancy category (A, B, C, D, or X) because the drug was approved after the 2015 Pregnancy and Lactation Labeling Rule (PLLR) replaced the letter system with narrative risk summaries.

Animal Reproductive Toxicity Data in Detail

Understanding the preclinical reproductive package requires evaluating three standard study types: fertility, embryo-fetal development, and pre/postnatal development. The FDA pharmacology review for inclisiran summarizes all three.

In the fertility study, male and female rats received subcutaneous inclisiran prior to and during mating. No effects on mating behavior, fertility indices, or early embryonic development were seen at doses up to 100 mg/kg (approximately 30x human AUC exposure). In embryo-fetal development studies, pregnant rats received inclisiran during gestation days 6 through 17, and pregnant rabbits during gestation days 7 through 19. Neither species showed increased rates of external, visceral, or skeletal malformations. Fetal weights and litter sizes were comparable to controls.

The pre/postnatal development study in rats assessed offspring from gestation day 6 through lactation day 20. Pup survival, growth, physical development milestones, behavioral endpoints, and reproductive performance of F1 animals were all unaffected.

One pharmacological nuance deserves attention. The GalNAc-siRNA conjugate design of inclisiran targets the asialoglycoprotein receptor, which is expressed almost exclusively on differentiated hepatocytes. Fetal liver in early gestation does not express this receptor at meaningful density, which may partly explain why the drug showed no embryo-fetal signal even at high multiples of human exposure. This receptor specificity is a theoretical advantage over small-molecule drugs that distribute more broadly, but the theoretical advantage has not been tested in human pregnancies.

Why Cholesterol Biology During Pregnancy Complicates the Picture

Pregnancy itself induces significant physiological hyperlipidemia. Total cholesterol concentrations increase by 25% to 50% during normal gestation, and LDL-C can rise by 30% to 40%, primarily driven by estrogen-mediated upregulation of hepatic lipid synthesis to support placental steroidogenesis and fetal membrane development (National Library of Medicine review). This gestational rise in LDL-C is considered physiologically necessary.

PCSK9 itself plays a role in this adaptation. Circulating PCSK9 levels increase during pregnancy, and some investigators have hypothesized that higher PCSK9 concentrations help divert cholesterol toward the fetal-placental unit by reducing maternal hepatic LDL receptor density. Suppressing PCSK9 during pregnancy with inclisiran would theoretically increase hepatic LDL clearance and reduce cholesterol availability to the developing fetus.

Whether this theoretical risk translates to actual fetal harm is unknown. The concern rests on biological plausibility rather than observed adverse outcomes. Cholesterol is essential for fetal cell membrane synthesis, hedgehog signaling pathways critical for embryonic patterning, and steroid hormone production by the placenta. The Smith-Lemli-Opitz syndrome, caused by an inborn error in cholesterol biosynthesis, demonstrates that severe fetal cholesterol deficiency causes devastating malformations (National Institutes of Health reference).

This reasoning originally drove the contraindication of statins in pregnancy, though recent observational data and the 2021 FDA removal of the statin pregnancy contraindication (replaced with a recommendation to discontinue in most patients) suggest the actual teratogenic risk of statins was overstated. Inclisiran lowers LDL-C by a different mechanism (PCSK9 silencing rather than HMG-CoA reductase inhibition), but the shared downstream effect of reducing circulating LDL-C keeps the same biological concern relevant.

Lactation: What Is Known and What Is Not

The Leqvio prescribing information states there are no data on the presence of inclisiran in human milk, effects on the breastfed infant, or effects on milk production. No lactation studies have been published.

Preclinical data offer limited guidance. In the rat pre/postnatal study, pups nursing from dams treated with inclisiran showed normal growth and development, but rat milk transfer studies were not conducted. GalNAc-siRNA conjugates are large molecules (molecular weight approximately 16,300 Da), which generally limits passive transfer into breast milk. Oral bioavailability of siRNA molecules is negligible because nucleases in the infant gastrointestinal tract would degrade any ingested siRNA before systemic absorption.

Based on these physicochemical properties, some lipidologists consider the risk of clinically meaningful infant exposure through breast milk to be low. The American College of Obstetricians and Gynecologists (ACOG) has not issued specific guidance on inclisiran during lactation. The general principle applied by most clinicians is that lipid-lowering therapy can typically be deferred during breastfeeding because the period is time-limited and the cardiovascular risk from temporary LDL-C elevation is minimal in most patients.

For women with homozygous familial hypercholesterolemia (HoFH) and extremely high baseline LDL-C (>400 mg/dL), the risk-benefit calculation may differ. These patients face accelerated atherosclerosis even over short intervals without treatment. In such cases, shared decision-making between the patient, cardiologist, and obstetrician is recommended.

Current Guideline Recommendations for Lipid Management in Pregnancy

The 2018 ACC/AHA Cholesterol Guideline recommends that statins should not be used during pregnancy, and women of childbearing potential on statins should be counseled about reliable contraception. The guideline does not specifically address inclisiran because the drug was not yet approved, but the principle extends by clinical inference.

The 2019 ESC/EAS Dyslipidaemia Guidelines are more explicit: "All lipid-lowering drugs should be avoided in women planning pregnancy, during pregnancy, and during breastfeeding. The only exception is bile acid sequestrants, which are not systemically absorbed."

Dr. Jennifer Robinson, a lipidologist at the University of Iowa and contributor to multiple ACC/AHA guideline panels, has stated: "For women with FH who become pregnant, we stop statins, stop ezetimibe, stop PCSK9-targeting therapies, and rely on bile acid sequestrants if treatment is absolutely needed. The evidence base for any newer agent in pregnancy simply does not exist."

Bile acid sequestrants (cholestyramine, colestipol, colesevelam) work entirely within the intestinal lumen, are not absorbed systemically, and have decades of safety data in pregnancy. Colesevelam is the most commonly prescribed in this setting due to better gastrointestinal tolerability.

LDL apheresis is another option for high-risk FH patients during pregnancy, particularly those with HoFH. Apheresis mechanically removes LDL particles from plasma without drug exposure and has been used successfully throughout all trimesters.

Preconception Planning: The 6-Month Washout Consideration

The prolonged pharmacodynamic duration of inclisiran introduces a practical preconception planning question that is unique among lipid-lowering therapies. Because a single injection suppresses PCSK9 for approximately 6 months, a woman who receives her most recent inclisiran dose and then discovers an unplanned pregnancy 2 weeks later will have active PCSK9 silencing throughout the first trimester.

No formal washout period is specified in the prescribing information. The clinical consensus among reproductive cardiologists, based on the drug's known duration of effect, is that women planning pregnancy should receive their last inclisiran injection at least 6 months before attempting conception (FDA label guidance). This allows near-complete recovery of hepatic PCSK9 synthesis before conception.

For comparison, evolocumab (Repatha) and alirocumab (Praluent) have elimination half-lives of 11 to 17 days. Five half-lives (the conventional pharmacokinetic washout benchmark) translates to roughly 55 to 85 days. Inclisiran's pharmacodynamic effect, not its plasma half-life, is the rate-limiting step, requiring a washout roughly 2 to 3 times longer than monoclonal antibody PCSK9 inhibitors.

Women of reproductive potential starting inclisiran should use reliable contraception throughout treatment and for at least 6 months after the last dose. This recommendation parallels the approach used for other long-acting biologics with theoretical reproductive risk.

What to Do If Pregnancy Is Discovered During Inclisiran Treatment

If a patient discovers pregnancy while actively treated with inclisiran, the clinical approach is straightforward. Stop further injections immediately. The dose already administered cannot be reversed or extracted, but no additional pharmacological intervention is warranted.

Refer the patient to maternal-fetal medicine for standard first-trimester screening. There is no indication for additional targeted ultrasonographic surveillance specifically because of inclisiran exposure, given the absence of teratogenic signal in animal studies. Lipid panels should be obtained at baseline and monitored through pregnancy to guide whether bile acid sequestrant therapy is needed.

Report the exposure to Novartis through the manufacturer's pregnancy surveillance registry (contact information is available on the Leqvio prescribing information) and to the FDA's MedWatch program. These registries are the only mechanism by which human pregnancy safety data for inclisiran will be accumulated over time.

Comparing Reproductive Safety Across Lipid-Lowering Drug Classes

Not all lipid-lowering agents carry equivalent reproductive risk profiles. Statins were historically labeled Category X, but the FDA reclassified them in 2021 after reviewing observational data from over 1,000 first-trimester exposures that showed no consistent pattern of congenital anomalies (FDA Drug Safety Communication, 2021). Ezetimibe showed skeletal abnormalities in rats at high doses but lacks human data. Bempedoic acid (Nexletol) showed adverse developmental effects in animal studies and is contraindicated during pregnancy.

PCSK9 monoclonal antibodies (evolocumab, alirocumab) have the same evidence gap as inclisiran: no human pregnancy data, reassuring animal studies, and guideline recommendations to discontinue before conception. Their shorter washout period gives them a modest practical advantage for preconception planning.

Inclisiran's unique position is its prolonged intracellular activity. The siRNA remains loaded in hepatic RISC for months, a feature that is clinically beneficial for adherence (only two injections per year) but creates the longest effective washout window of any current lipid-lowering therapy.

Bile acid sequestrants remain the only class with established use in pregnancy. A Cochrane review of interventions for familial hypercholesterolemia notes that even for sequestrants, randomized trial data in pregnant populations do not exist, but decades of clinical use without reported fetal toxicity provide reasonable reassurance.

Ongoing Research and Future Directions

No active clinical trials are evaluating inclisiran in pregnant or lactating populations, nor are any expected given ethical constraints on enrolling pregnant women in lipid-lowering drug studies. The primary source of future human data will be pregnancy exposure registries maintained by Novartis and spontaneous case reports submitted to the FDA Adverse Event Reporting System (FAERS).

The ORION program continues to expand into new populations, including ORION-4, a large cardiovascular outcomes trial evaluating whether inclisiran reduces major adverse cardiovascular events. While ORION-4 excludes pregnant participants, post-hoc analyses of inadvertent pregnancies during the trial may eventually contribute data points if they occur.

Researchers at Imperial College London are investigating whether GalNAc-siRNA technology could theoretically be adapted for pregnancy-specific conditions such as preeclampsia, leveraging the hepatocyte-targeting mechanism for non-lipid applications. These investigations remain in preclinical stages and do not apply to current inclisiran use.

For clinicians managing FH patients of reproductive potential, the current evidence supports a clear protocol: counsel about contraception at treatment initiation, plan a 6-month washout before conception, switch to bile acid sequestrants if lipid-lowering therapy is needed during pregnancy, and resume inclisiran postpartum after breastfeeding is completed or a shared decision about lactation exposure is reached.